Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 1789Neoplasms 1516Carcinoma, Non-Small-Cell Lung 1053Prostatic Neoplasms 965Colorectal Neoplasms 889Lung Neoplasms 809Pancreatic Neoplasms 583Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 540Stomach Neoplasms 523Ovarian Neoplasms 513Neoplasm Metastasis 492Multiple Myeloma 491Recurrence 417Melanoma 390Squamous Cell Carcinoma of Head and Neck 374Uterine Cervical Neoplasms 366Brain Neoplasms 364Head and Neck Neoplasms 355Esophageal Neoplasms 320Precursor Cell Lymphoblastic Leukemia-Lymphoma 313Endometrial Neoplasms 311Lymphoma 309Triple Negative Breast Neoplasms 301Glioblastoma 298Rectal Neoplasms 284Urinary Bladder Neoplasms 268Sarcoma 266Hematologic Neoplasms 266Colonic Neoplasms 257

Interventions

Specimen Handling 2nedaplatin 1X-Rays 1Relaxation Therapy 1Protons 1Proton Therapy 1Platinum Compounds 1Physical Therapy Modalities 1Pemetrexed 1Paclitaxel 1Docetaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Resectable Lung Non-Small Cell Carcinoma × Clear all
NCT07584239 2026-05-26

Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial

Ohio State University Comprehensive Cancer Center

Phase NA Recruiting
30 enrolled

Resectable Lung Non-Small Cell Carcinoma

NCT06008730 2025-11-10

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Emory University

Phase 2 Recruiting
20 enrolled

Resectable Lung Non-Small Cell Carcinoma

NCT06775275 2025-01-15

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
60 enrolled

Resectable Lung Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡